Synthesis and Anticancer Activity of Some New Pyrazolo[3,4-d]pyrimidin-4-one Derivatives-Reference-Cited by-同舟云学术

Synthesis and Anticancer Activity of Some New Pyrazolo[3,4-d]pyrimidin-4-one Derivatives

Published:2014-03-18 Issue:3 Volume:19 Page:3297-3309
ISSN:1420-3049
Container-title:Molecules
language:en
Short-container-title:Molecules

Author:

Abdellatif Khaled,Abdelall Eman,Abdelgawad Mohamed,Ahmed Rasha,Bakr Rania

Publisher

MDPI AG

Subject

Chemistry (miscellaneous),Analytical Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Molecular Medicine,Drug Discovery,Pharmaceutical Science

Link

http://www.mdpi.com/1420-3049/19/3/3297/pdf

Reference21 articles.

1. Targeted therapy for cancer;Wu;J. Cancer Mol.,2006

2. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

3. The Molecular Basis of Cancer and the Development of Targeted Therapy

4. Potential Purine Antagonists. VI. Synthesis of 1-Alkyl- and 1-Aryl-4-substituted Pyrazolo[3,4-d]pyrimidines1,2

5. Synthesis of some new biologically active sulfur compounds containing pyrazolo[3,4-d]pyrimidine moiety;Ismail;Phosphor. Sulfur Silicon,2003

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis and Biological Evaluation of New Benzochromenopyrimidines for the Therapy of Colon and Lung Cancer;ChemistrySelect;2024-01-11

2. Synthesis, Antibacterial, and Antifungal Evaluation of New Class of Pyrimido[4,5-d]pyrimidine, Pyrazolo[3,4-d]pyrimidine, and Pyrimido[4,5-b]quinoline Derived from α,α-Ketene Dithioacetals as fused Five and Six-membered Heterocycle Derivatives;Russian Journal of Bioorganic Chemistry;2023-11

3. Pyrazolo - Pyrimidines as Targeted Anticancer Scaffolds - A Comprehensive Review;Medicinal Chemistry;2023-10-25

4. Design, Synthesis, Docking Study of Pyrazolohydrazinopyrimidin‐4‐one Derivatives and Their Application as Antimicrobials;Chemistry & Biodiversity;2023-04-05

5. Design, synthesis, and docking studies of novel pyrazole-based scaffolds and their evaluation as VEGFR2 inhibitors in the treatment of prostate cancer;RSC Advances;2023